Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
276
-
Total 13F shares, excl. options
-
99.5M
-
Shares change
-
-2.43M
-
Total reported value, excl. options
-
$934M
-
Value change
-
-$6.85M
-
Put/Call ratio
-
0.6
-
Number of buys
-
146
-
Number of sells
-
-138
-
Price
-
$9.38
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2025
350 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 276 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 99.5M shares
of 108M outstanding shares and own 92.31% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (13M shares), VANGUARD GROUP INC (10.9M shares), BlackRock, Inc. (10M shares), MORGAN STANLEY (4.12M shares), STATE STREET CORP (4.04M shares), REGENERON PHARMACEUTICALS, INC. (3.7M shares), BAKER BROS. ADVISORS LP (2.68M shares), Sumitomo Mitsui Trust Group, Inc. (2.67M shares), Nikko Asset Management Americas, Inc. (2.67M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.61M shares).
This table shows the top 276 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.